EntreMed， Inc. is a NASDAQ listed public company with a stock code: ENMD. It is a clinical-stage pharmaceutical company employing a drug development strategy primarily in the United States and China to develop targeted therapeutics for the global oncology market. Its lead compound， ENMD-2076， a selective angiogenic kinase inhibitor， has completed several Phase 1 studies in solid tumors， multiple myeloma， and leukemia， and is currently completing a multi-center Phase 2 study in ovarian cancer. EntreMed， Inc. recently initiated a dual-institutional Phase 2 study of ENMD-2076 in triple-negative breast cancer and a Phase 2 study in soft tissue sarcoma. The Company has a wholly owned subsidiary， EntreMed (Beijing) Co. Ltd.， in Beijing， China with headquarters in Chaoyang business district. Additional information about EntreMed is available on the Company's web site at .  EntreMed， Inc.为美国NASDQ上市（股票代码ENMD）生物制药公司，致力于小分子靶向治疗肿瘤的创新药物的开发与产业化。目前主要在研药物ENMD-2076为一多靶点抗肿瘤药，可选择性抑制激光蛋白激酶、血管生成激酶抑与肿瘤细胞分裂相关的蛋白激酶。目前已在美国完成针对不同实体瘤、多发性骨髓瘤、白血病等的1期临床试验。研究表面单药对卵巢癌、乳腺癌、肝癌、肾癌、软组织肉瘤等具有明显的活性。现正开展一项针对卵巢癌的国际多中心2期临床试验。另外，公司近期启动了一项关于ENMD-2076治疗三阴乳腺癌的2期临床试验和一项治疗软组织肉瘤的2期临床。英创远达（北京）生物医药科技有限公司为EntreMed在北京设立的全资子公司，总部位于北京市朝阳区。更多信息请登录公司网站 了解。